Controversies in Neuro-Oncology

Bevacizumab Toxicity in Glioblastoma

Author(s): Dawit Aregawi and David Schiff

Pp: 46-50 (5)

DOI: 10.2174/978160805132811001010046

* (Excluding Mailing and Handling)


Bevacizumab recently received approval from the United States Food and Drug Administration for use in recurrent glioblastoma. Although, most patients tolerate bevacizumab with tolerable side effects, occasional patients sustain life-threatening complications and many others require medical management in order to continue on the drug. This chapter reviews the spectrum of bevacizumab complications in patients with malignant glioma, including mechanism when known as well as management.

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy